Innate Pharma S.A. (IPHA)

Innate Pharma Income Statement

Financials in millions EUR. Fiscal year is January - December.

Year	2023	2022	2021	2020	2019
Revenue	61.64	57.67	24.7	69.77	85.45
Revenue Growth (YoY)	6.88%	133.47%	-64.60%	-18.35%	-9.05%
Gross Profit	61.64	57.67	24.7	69.77	85.45
Selling, General & Admin	18.29	22.44	25.52	18.99	20.98
Research & Development	56.02	51.66	47	49.71	62.9
Other Operating Expenses	0	41	0	0	0
Operating Expenses	74.31	115.1	72.53	68.69	83.87
Operating Income	-12.67	-57.43	-47.83	1.08	1.58
Interest Expense / Income	1.84	5.32	4	6.76	4.98
Other Expense / Income	-6.93	-4.64	0.99	58.3	17.36
Pretax Income	-7.57	-58.1	-52.81	-63.98	-20.76
Net Income	-7.57	-58.1	-52.81	-63.98	-20.76
Shares Outstanding (Basic)	81	80	79	79	75
Shares Change	0.78%	1.10%	0.57%	5.18%	27.11%
EPS (Basic)	-0.09	-0.73	-0.66	-0.81	-0.31
EPS (Diluted)	-0.09	-0.73	-0.66	-0.81	-0.31
Free Cash Flow	-32.76	-19.69	-59.38	-52.67	33.65
Free Cash Flow Per Share	-0.41	-0.25	-0.75	-0.67	0.45
Gross Margin	100.00%	100.00%	100.00%	100.00%	100.00%
Operating Margin	-20.55%	-99.57%	-193.60%	1.55%	1.84%
Profit Margin	-12.28%	-100.74%	-213.78%	-91.70%	-24.29%
Free Cash Flow Margin	-53.14%	-34.14%	-240.37%	-75.48%	39.38%
EBITDA	-0.64	-7.38	-44.22	-0.42	0.75
EBITDA Margin	-1.04%	-12.79%	-178.99%	-0.61%	0.87%
Depreciation & Amortization	5.09	45.41	4.6	56.8	16.53
EBIT	-5.74	-52.78	-48.81	-57.22	-15.78
EBIT Margin	-9.30%	-91.52%	-197.60%	-82.01%	-18.47%

Source: Financials are provided by Nasdaq Data Link and sourced from audited reports submitted to the Securities and Exchange Commission (SEC).